Rare metals and immune markers in hip and knee tissue from patients having joint replacement
Official title: Molecular Mechanisms Underlying Hip and Knee Osteoarthritis in Patients Undergoing Primary Elective Arthroplasty
Run by Medical University of Warsaw · NCT07347821 · Data updated 2026-11-12
This project will see if levels of rare metals, trace elements, and certain immune markers are low in the joint tissue and blood of adults having hip or knee replacement for osteoarthritis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Medical University of Warsaw Academic / other |
| Locations | 1 site (Ostrów Mazowiecka, Masovian Voivodeship) |
| Status | Recruiting |
| Started | November 22, 2025 |
| Main results expected | December 2027 |
| Study ends | December 2028 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT07347821 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with hip or knee osteoarthritis who are scheduled for primary total hip or knee arthroplasty and can provide a complete set of good-quality tissue samples are ideal candidates.
✕Probably not a fit
Patients with autoimmune disease, genetic connective tissue or metabolic disorders, prior surgeries that altered the joint, revision arthroplasty, traumatic joint injury, or who do not consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, single-center project that collects tissue and blood from adults undergoing primary elective total hip or knee arthroplasty for osteoarthritis. Laboratory analyses will measure the content of selected rare metals and trace elements in joint tissue and serum, together with chosen immunological parameters such as cytokine levels. Patients with genetic connective tissue or metabolic disorders, autoimmune disease, prior joint-altering surgery, revision arthroplasty, or traumatic joint injury are excluded to reduce confounding. Findings will be compared across the collected samples to identify potential disturbances in metal content or immune markers that could inform future interventions.
Why it matters
Potential benefit: If successful, the results could point to metal deficiencies or immune alterations that might be corrected by targeted supplementation or immune-focused therapies to improve osteoarthritis care.
How similar studies have gone: Previous research has reported altered trace elements and cytokine patterns in osteoarthritis but results are inconsistent, so this combined tissue-and-serum approach is relatively novel and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old and more * patient qualified for primary TKA or primary THA * patient diagnosed with hip or knee osteoarthritis * a complete set of tissues of good quality and volume is available * does not meet the exclusion criteria. Exclusion Criteria: * lack of written consent to participate in the study or surgery * any private or professional relationship with the Investigators * genetic connective tissue diseases (e.g., Ehlers-Danlos syndrome and others) * genetic metabolic diseases (e.g., gout and others) * genetic diseases affecting the anatomy of the operated joint (e.g., dysplasia and others) * previous surgeries altering the anatomy of the examined joint (e.g., periacetabular osteotomy, unicompartmental endoprosthesis, and others) * patients undergoing revision after THA/TKA * autoimmune diseases in the patient's medical history * traumatic injury to the hip or knee joint * previous participation in the study.
Where it's running
-
Szpital Powiatowy im. M. Skłodowskiej-Curie
Ostrów Mazowiecka, Masovian Voivodeship, Poland Recruiting
Study contacts
- Study coordinator: Artur Stolarczyk, Professor
- Email: artur.stolarczyk@wum.edu.pl
- Phone: +48224735218
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Suzetrigine for pain relief after knee replacement
This trial tests whether suzetrigine can reduce opioid use after a total knee replacement compared with placebo.
-
Suzetrigine for pain control after primary total hip replacement
This will test whether taking Suzetrigine before surgery and for seven days afterward reduces opioid use and improves pain control in adults having a primary total hip replacement.
-
Three-week intensive rehabilitation for people with ongoing problems after total hip or knee replacement.
This program tests whether three weeks of intensive rehabilitation helps people who continue to have physical problems after total hip or knee replacement.
-
NPT Feasibility in Knee Osteoarthritis
This study tests whether NRPT can be safely given to adults with knee osteoarthritis and whether it shows early signals of benefit.
-
Aquatic exercise for knee osteoarthritis and central sensitization
A water-based exercise program is being tested to see if it helps people aged 40–65 with knee osteoarthritis who also have central sensitization.
-
Ceramic hip resurfacing vs total hip arthroplasty for hip OA
This trial tests whether ceramic hip resurfacing helps people with hip OA walk farther each day than a modern total hip replacement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.